APA (7th ed.) Citation

Martin Haljeta Friedrichsen, Lars Endahl, Frederik Flindt Kreiner, Ronald Goldwater, Martin Kankam, Søren Toubro, & Sune Boris Nygård. (2024). Corrigendum to "Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity" [Mol Metab 78 (2023) 101801]. Elsevier.

Chicago Style (17th ed.) Citation

Martin Haljeta Friedrichsen, Lars Endahl, Frederik Flindt Kreiner, Ronald Goldwater, Martin Kankam, Søren Toubro, and Sune Boris Nygård. Corrigendum to "Results from Three Phase 1 trials of NNC9204-1177, a Glucagon/GLP-1 Receptor Co-agonist: Effects on Weight Loss and Safety in Adults with Overweight or Obesity" [Mol Metab 78 (2023) 101801]. Elsevier, 2024.

MLA (9th ed.) Citation

Martin Haljeta Friedrichsen, et al. Corrigendum to "Results from Three Phase 1 trials of NNC9204-1177, a Glucagon/GLP-1 Receptor Co-agonist: Effects on Weight Loss and Safety in Adults with Overweight or Obesity" [Mol Metab 78 (2023) 101801]. Elsevier, 2024.